Sugi Predict

Sugi Predict / Compounds / SCHEMBL2683971

SCHEMBL2683971

SCHEMBL2683971

Cc1ncc(COP(=O)(OCc2cnc(C)c(O)c2CN)OCc2cnc(C)c(O)c2CN)c(CN)c1O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.60
▸ ESR1 P03372 1/20 0.50
▸ PTGS1 P23219 1/20 0.50
▸ ACP1 P24666 1/20 0.50
▸ PDE4A P27815 1/20 0.50
▸ P2RX1 P51575 1/20 0.50
▸ P2RX2 Q9UBL9 1/20 0.50
▸ PNPO Q9NVS9 1/20 0.49
▸ KDM4E B2RXH2 3/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ HPGD P15428 2/20 0.45
▸ HSD17B10 Q99714 1/20 0.45
▸ SGPL1 O95470 2/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ AOX1 Q06278 1/20 0.38
▸ TRIM24 O15164 1/20 0.37
▸ TRIM33 Q9UPN9 1/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridoxamine Phosphate Anhydrous SCHEMBL29619879 0.90 ESR1 (0.63) LMNAESR1PTGS1ACP1PDE4A
Pyridoxamine Phosphate Anhydrous SCHEMBL43832 0.90 ESR1 (0.63) LMNAESR1PTGS1ACP1PDE4A
Pyridoxamine Phosphate Anhydrous SCHEMBL10942609 0.89 ESR1 (0.61) LMNAESR1PTGS1ACP1PDE4A
SCHEMBL16171284 0.89 LMNA (0.57) LMNAESR1PTGS1ACP1PDE4A
SCHEMBL25664909 0.80 LMNA (0.48) LMNAESR1PTGS1ACP1PDE4A
SCHEMBL16560502 0.80 LMNA (0.66) LMNAESR1PTGS1ACP1PDE4A
SCHEMBL17145899 0.79 LMNA (0.60) LMNAESR1PTGS1ACP1PDE4A
SCHEMBL25664896 0.79 LMNA (0.60) LMNAESR1PTGS1ACP1PDE4A
SCHEMBL14682707 0.79 LMNA (0.74) LMNAESR1PTGS1ACP1PDE4A
Pyridoxamine SCHEMBL43833 0.79 LMNA (0.84) LMNAESR1PTGS1ACP1PDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12011496-B2 Topical macqui berry formulation Tracie Martyn International, Inc. (US) 2024-06-18 — — US disclosed
US-20220105017-A1 TOPICAL MACQUI BERRY FORMULATION TRACIE MARTYN INT INC (US) 2022-04-07 — — US disclosed
US-10993897-B2 Topical macqui berry formula Tracie Martyn International, Inc. (US) 2021-05-04 — — US disclosed
US-20190151227-A1 TOPICAL MACQUI BERRY FORMULA TRACIE MARTYN INT INC (US) 2019-05-23 — — US disclosed
US-20170027853-A1 TOPICAL MACQUI BERRY FORMULATION TRACIE MARTYN INTERNATIONAL, LLC 2017-02-02 — — US disclosed
US-9463153-B2 Topical macqui berry formulation Trade Martyn International, LLC (US) 2016-10-11 — — US disclosed
US-20150150770-A1 METHODS OF TREATING SKIN TRACIE MARTYN INTERNATIONAL INC (US) 2015-06-04 — — US disclosed
US-20140377338-A1 TOPICAL MACQUI BERRY FORMULATION TRACIE MARTYN INTERNATIONAL, LLC 2014-12-25 — — US disclosed
US-8828458-B2 Topical macqui berry formulation TRACIE MARTYN INTERNATIONAL, LLC 2014-09-09 — — US disclosed
US-20140155961-A1 METHODS OF TREATING SKIN Tracie Martyn International, Inc. (US) 2014-06-05 — — US disclosed
US-20140134222-A1 TOPICAL BENFOTIAMINE AND PYRIDOXAMINE COMPOSITIONS Tracie Martyn International, Inc. (US) 2014-05-15 — — US disclosed
US-20120114719-A1 Topical Macqui Berry Formulation TRACIE MARTYN INTERNATIONAL, LLC (US) 2012-05-10 — — US disclosed
US-20100272790-A1 Methods of Treating Skin TRACIE MARTYN INTERNATIONAL, LLC (US) 2010-10-28 — — US disclosed
US-7776915-B2 Topical formulations and methods of use TRACIE MARTYN INTERNATIONAL, LLC (US) 2010-08-17 — — US disclosed
US-20100151061-A1 METHODS OF USING BENFOTIAMINE AND PYRIDOXAMINE COMPOSITIONS TRACIE MARTYN INTERNATIONAL, LLC (US) 2010-06-17 — — US disclosed
US-7666442-B2 Topical compositions comprising benfotiamine and pyridoxamine TRACIE MARTYN INTERNATIONAL, LLC (US) 2010-02-23 — — US disclosed
US-20070065396-A1 Topical macqui berry formulation TRACIE MARTYN INTERNATIONAL, LLC 2007-03-22 — — US disclosed
US-20060216251-A1 Topical formulations and methods of use TRACIE MARTYN INTERNATIONAL, LLC (US) 2006-09-28 — — US disclosed
WO-2006026713-A2 TOPICAL BENFOTIAMINE AND PYRIDOXAMINE COMPOSITIONS TRACIE MARTYN INTERNATIONAL, LLC (US) 2006-03-09 — — WO disclosed
US-20060045896-A1 Topical compositions comprising benfotiamine and pyridoxamine TRACIE MARTYN INTERNATIONAL, LLC 2006-03-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100151061-A1 METHODS OF USING BENFOTIAMINE AND PYRIDOXAMINE COMPOSITIONS AGER, LOX, LPO LMNA 485/4885ESR1 3607/4885PTGS1 330/4885
US-20140155961-A1 METHODS OF TREATING SKIN CUTA, LIPA, DLAT LMNA 73/4885ESR1 4861/4885PTGS1 2158/4885
US-20100272790-A1 Methods of Treating Skin CUTA, LIPA, DLAT LMNA 73/4885ESR1 4861/4885PTGS1 2158/4885
US-20150150770-A1 METHODS OF TREATING SKIN CUTA, LIPA, DLAT LMNA 73/4885ESR1 4861/4885PTGS1 2158/4885
US-20140134222-A1 TOPICAL BENFOTIAMINE AND PYRIDOXAMINE COMPOSITIONS AGER, LOX, LPO LMNA 552/4885ESR1 3118/4885PTGS1 444/4885
US-20060216251-A1 Topical formulations and methods of use CPT1B, SLC25A20, CPT1A LMNA 200/4885ESR1 4868/4885PTGS1 1349/4885
US-20060045896-A1 Topical compositions comprising benfotiamine and pyridoxamine AGER, LPO, LOX LMNA 458/4885ESR1 3169/4885PTGS1 424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.